Local control in metastatic neuroblastoma in children over 1 year of age

被引:29
作者
De Ioris, Maria Antonietta [1 ]
Crocoli, Alessandro [2 ]
Contoli, Benedetta [1 ]
Garganese, Maria Carmen [3 ]
Natali, Gianluigi [3 ]
Toma, Paolo [3 ]
Jenkner, Alessandro [1 ]
Boldrini, Renata [4 ]
De Pasquale, Maria Debora [1 ]
Milano, Giuseppe Maria [1 ]
Madafferi, Silvia [2 ]
Castellano, Aurora [1 ]
Locatelli, Franco [1 ,5 ]
Inserra, Alessandro [2 ]
机构
[1] Osped Pediat Bambino Gesu, IRCCS, Dept Hematol Oncol, Rome, Italy
[2] Dept Surg, Rome, Italy
[3] Dept Imaging, Rome, Italy
[4] Bambino Gesu Pediat Hosp, Dept Pathol, Rome, Italy
[5] Univ Pavia, I-27100 Pavia, Italy
关键词
Neuroblastoma; Surgery; Metastasis; Radiotherapy; Prognosis; HIGH-RISK NEUROBLASTOMA; RESEARCH-HOSPITAL EXPERIENCE; COMPLETE SURGICAL RESECTION; STAGE; 4; NEUROBLASTOMA; GROSS TOTAL RESECTION; RANDOMIZED-TRIAL; INTENSIVE CHEMOTHERAPY; 13-CIS-RETINOIC ACID; SURVIVAL; SURGERY;
D O I
10.1186/s12885-015-1082-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Local control is always considered in metastatic neuroblastoma (NBL). The aim of this study is to evaluate the impact of radical surgery on survival in children over 1 year of age. Methods: Fifty-eight patients older than 1 year of age with metastatic NBL were treated with conventional plus high-dose chemotherapy with or without addition of local radiotherapy (RT, 21Gy). Surgery was classified as radical surgery (complete resection and gross total resection) or non-radical surgery. The Kaplan-Meier method and the Cox proportional hazard model were used to calculate the probability of progression free and overall survival (PFS and OS) and for multivariate analysis. Results: The 5-year PFS and OS for patients with radical surgery were 26% (95% CI 14-40%) and 38% (95% CI 23-53%) respectively, while the PFS and OS for patients without radical surgery were 33% (95% CI 10-59%) and 31% (95% CI 10-55%) (respectively, P 0.85 and P 0.42). The 5-year PFS and OS for patients who received RT were 36% (95% CI 19-53%) and 46% (95% CI 26-64%) respectively, while the 5-year PFS and OS for patients who did not receive RT were 22% (95% CI 9-38%) and 27% (95% CI 13-42%) respectively (P 0.02 for PFS). Multivariate analysis confirmed the role of well-known prognostic factors, such as the presence of MYCN amplification, age and response before high-dose chemotherapy. Conclusions: Our data suggest that the degree of resection does not influence survival in metastatic NBL patients treated with high-dose chemotherapy; local RT contributes to local disease control.
引用
收藏
页数:7
相关论文
共 28 条
[1]   Efficacy of complete resection for high-risk neuroblastoma: A children's cancer group study [J].
Adkins, ES ;
Sawin, R ;
Gerbing, RB ;
London, WB ;
Matthay, KK ;
Haase, GM .
JOURNAL OF PEDIATRIC SURGERY, 2004, 39 (06) :931-936
[2]   Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial [J].
Berthold, F ;
Boos, J ;
Burdach, S ;
Erttmann, R ;
Henze, G ;
Hermann, J ;
Klingebiel, T ;
Kremens, B ;
Schilling, FH ;
Schrappe, M ;
Simon, T ;
Hero, B .
LANCET ONCOLOGY, 2005, 6 (09) :649-658
[3]   REVISIONS OF THE INTERNATIONAL CRITERIA FOR NEUROBLASTOMA DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT [J].
BRODEUR, GM ;
PRITCHARD, J ;
BERTHOLD, F ;
CARLSEN, NLT ;
CASTEL, V ;
CASTLEBERRY, RP ;
DEBERNARDI, B ;
EVANS, AE ;
FAVROT, M ;
HEDBORG, F ;
KANEKO, M ;
KEMSHEAD, J ;
LAMPERT, F ;
LEE, REJ ;
LOOK, AT ;
PEARSON, ADJ ;
PHILIP, T ;
ROALD, B ;
SAWADA, T ;
SEEGER, RC ;
TSUCHIDA, Y ;
VOUTE, PA .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) :1466-1477
[4]   The role of surgery in stage IV neuroblastoma [J].
Castel, V ;
Tovar, JA ;
Costa, E ;
Cuadros, J ;
Ruiz, A ;
Rollan, V ;
Ruiz-Jimenez, JI ;
Perez-Hernández, R ;
Cañete, A .
JOURNAL OF PEDIATRIC SURGERY, 2002, 37 (11) :1574-1578
[5]   Surgical risk factors in primary surgery for localized neuroblastoma:: The LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group [J].
Cecchetto, G ;
Mosseri, V ;
De Bernardi, B ;
Helardot, P ;
Monclair, T ;
Costa, E ;
Horcher, E ;
Neuenschwander, S ;
Tomà, P ;
Rizzo, A ;
Michon, J ;
Holmes, K .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) :8483-8489
[6]  
De Ioris MA, 2012, ANTICANCER RES, V32, P5527
[7]   Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma [J].
De Ioris, Maria Antonietta ;
Castellano, Aurora ;
Ilari, Ilaria ;
Garganese, Maria Carmen ;
Natali, Gianluigi ;
Inserra, Alessandro ;
De Vito, Rita ;
Rava, Lucilla ;
De Pasquale, Maria Debora ;
Locatelli, Franco ;
Donfrancesco, Alberto ;
Jenkner, Alessandro .
EUROPEAN JOURNAL OF CANCER, 2011, 47 (04) :572-578
[8]   Ifosfamide/carboplatin/etoposide (ICE) as front-line, topotecan/cyclophosphamide as second-line and oral temozolomide as third-line treatment for advanced neuroblastoma over one year of age [J].
Donfrancesco, A ;
Jenkner, A ;
Castellano, A ;
Ilari, I ;
Milano, GM ;
De Sio, L ;
Cozza, R ;
Fidani, P ;
Deb, G ;
De Laurentis, C ;
Inserra, A ;
Dominici, C .
ACTA PAEDIATRICA, 2004, 93 :6-11
[9]  
Giraldo MZ., 2013, REV COLOMB ANESTESIO, V41, P44
[10]   Impact of radiotherapy for high-risk neuroblastoma: A children's cancer group study [J].
Haas-Kogan, DA ;
Swift, PS ;
Selch, M ;
Haase, GM ;
Seeger, RC ;
Gerbing, RB ;
Stram, DO ;
Matthay, KK .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (01) :28-39